---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-23-000116"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2023-10-18T23:59:59+00:00"
generated_at: "2026-06-09T21:50:21.112214+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Caribou Biosciences gets FDA IND clearance for CB-012 allogeneic CAR-T in r/r AML

## Summary
- FDA cleared IND for CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy for relapsed/refractory AML.
- AMpLify Phase 1 trial planned to start patient enrollment by mid-2024; first dose level at 25×10^6 CAR-T cells.
- CB-012 is the first allogeneic CAR-T with both PD-1 checkpoint disruption and B2M–HLA-E immune cloaking.
- CB-012 is Caribou's third off-the-shelf CAR-T therapy to enter clinical development.
- AML has ~20,380 new US cases in 2023; median survival for r/r AML is typically <7 months.

## SEC filing metadata
- accession: 0001619856-23-000116
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2023-10-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000116/0001619856-23-000116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000116/crbu-20231018.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-23-000116
- JSON: https://secwatch.observer/filing/0001619856-23-000116.json
- Plain text: https://secwatch.observer/filing/0001619856-23-000116.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.